logo
Plus   Neg
Share
Email

DCC CFO Fergal O'Dwyer To Retire - Quick Facts

DCC plc.(DCC.L) said Monday that Fergal O'Dwyer, who has been Chief Financial Officer since 1994, has decided to retire from the Group after 31 years of service. He will stand down from his executive position and from the Board following the conclusion of DCC's Annual General Meeting on 17 July 2020.

Fergal will be succeeded as Chief Financial Officer by Kevin Lucey, Head of Capital Markets, who will be appointed to the Board of DCC as an Executive Director, following the conclusion of the Annual General Meeting.

Kevin joined DCC in 2010. He has been Head of Capital Markets since 2017 and was previously the Head of Group Finance (2015 to 2017) and Finance & Development Director of DCC Technology (2010 to 2015).

Before joining to DCC, Kevin was Chief Financial Officer and a Director of a leading Irish private equity firm.

Separately, DCC said it appointed Tufan Erginbilgic as a non-executive Director and a member of the Remuneration Committee and of the Nomination and Governance Committee, with effect from 6 April 2020.

Tufan has been BP's Downstream Chief Executive, and a member of its executive team, since 2014, with responsibility for BP's global fuels, lubricants and petrochemicals businesses. He plans to leave this position at the end of March 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT